Form 4: Evolent Health CFO Granted Performance Share Units

Evolent Health's Chief Financial Officer, Mario Ramos, was granted 429,041 performance-based share units tied to future stock price performance and service conditions.

Summary

• Mario Ramos, Chief Financial Officer of Evolent Health, Inc. (EVH), was granted 429,041 performance-based share units (PSUs).
• The grant was made pursuant to the Evolent Health, Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan.
• These PSUs are subject to earning based on specific stock price performance conditions between March 1, 2027, and February 28, 2029.
• Earning of the PSUs also requires satisfying certain service-based conditions.
• The reported 429,041 PSUs represent the target level, with the actual amount earned potentially ranging from 0% to 250% of this target.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a standard and generally positive corporate governance action, aligning executive incentives with shareholder value, which is a common and expected practice.

Positives

• Aligns the Chief Financial Officer's incentives with shareholder interests through performance-based equity.
• Motivates long-term performance and retention of key management personnel.
• Utilizes an established incentive compensation plan (Amended and Restated 2015 Omnibus Incentive Compensation Plan).

Risks

• The PSUs may not be earned if the specified stock price performance conditions are not met.
• The PSUs may not be earned if service-based conditions are not satisfied.
• Potential dilution for existing shareholders if a significant number of PSUs vest at the maximum level.

Future Outlook

The future outlook for Mario Ramos's compensation is tied to Evolent Health's stock price performance between March 1, 2027, and February 28, 2029, and his continued service. The potential payout ranges from 0% to 250% of the target 429,041 PSUs.

Industry Context

StockSavvy.ai notes that performance-based share units are a common form of executive compensation in the healthcare technology and services industry. This grant aligns Evolent Health with prevalent practices designed to incentivize long-term value creation and retain key leadership.

Comparison to Industry Standards

• Performance-based equity grants are a standard component of executive compensation packages across the healthcare and technology sectors, similar to practices at companies like Teladoc Health (TDOC) or Veeva Systems (VEEV).
• The structure, tying vesting to both stock price performance and service conditions, is consistent with best practices aimed at aligning executive interests with long-term shareholder value.
• The potential payout range of 0% to 250% of target is also within typical industry ranges for such incentive plans, balancing risk and reward for executives.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased long-term value if stock price performance conditions are met, but also potential for dilution if PSUs vest at higher levels.
• Employees: Signals continued commitment to executive retention and performance-based compensation structures.

Next Steps

• Evolent Health's stock price performance will be monitored from March 1, 2027, to February 28, 2029, to determine the vesting of the PSUs.
• Mario Ramos must continue to satisfy service-based conditions for the PSUs to be earned.

Key Dates

Recommendation

This Form 4 filing reports a routine executive equity grant, which is a standard practice for public companies to incentivize management. It does not contain information that would typically warrant a change in investment recommendation, thus a "hold" is appropriate as it reflects a neutral event in the context of broader investment decisions.

Keywords

Evolent Health, EVH, Mario Ramos, CFO, Performance Share Units, PSUs, Executive Compensation, Equity Grant, Incentive Plan, Form 4, Insider Transaction